Neuphoria Therapeutics (NEUP) Liabilities and Shareholders Equity (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $34.8 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 13.34% year-over-year to $34.8 million in Q1 2026; TTM through Mar 2026 was $127.3 million, a 28.05% increase from a year earlier, with the FY2025 full-year figure at $28.6 million, up 3.4% from the prior year.
• Liabilities and Shareholders Equity was $34.8 million for Q1 2026 at Neuphoria Therapeutics, down from $36.6 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $46.8 million in Q2 2022 and troughed at $18.2 million in Q4 2024.
• A 5-year average of $30.2 million and a median of $28.7 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity plunged 38.56% in 2023 and jumped 101.44% in 2025, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $46.8 million in 2022, then tumbled by 38.56% to $28.7 million in 2023, then tumbled by 36.79% to $18.2 million in 2024, then surged by 101.44% to $36.6 million in 2025, then fell by 4.89% to $34.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $34.8 million (Q1 2026), $36.6 million (Q4 2025), and $27.3 million (Q3 2025), per Business Quant data.